drugset / Trial / NCT00722358
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary purpose of this study is to assess the change in HCV RNA during dosing with BMS-650032 and during the follow-up period in subjects with chronic hepatitis C infection
Timeline
- Start
- 2008-12
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Asunaprevir | Small molecule | 200 mg | Oral |
| Comparator | Asunaprevir | Small molecule | 400 mg | Oral |
| Comparator | Asunaprevir | Small molecule | 600 mg | Oral |